# Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine

> **NCT01696123** · PHASE2 · COMPLETED · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 125 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** MLC601

## Key facts

- **NCT ID:** NCT01696123
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-08
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2012-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696123, "Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01696123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*